Subscribe Us

header ads

Recents

header ads

Drug Discovery Outsourcing Market Size to Attain USD 6.55 Billion By 2030

 The drug discovery outsourcing market size is poised to grow by $ 6.55 billion by 2030 from $ 3.86 Billion in 2022, exhibiting a CAGR of 6.8% during the forecast period 2022-2030. 

Drug Discovery Outsourcing Market Size 2022 to 2030

 

The main objective of this report is to define, describe, and forecast the global market by types, application, manufacturers, and regions. The report provides detailed information about the major factors (drivers, restraints, opportunities, and industry-specific challenges) influencing the growth of the market. The report aims to strategically analyze the micro markets with respect to individual growth trends, prospects, and contributions to the global market. The report also attempts to forecast the market size of the 5 main regions: North America, Europe, Asia Pacific (APAC), Middle East and Africa (MEA), and Latin America. It strategically profiles the key market players and comprehensively analyzes their core competencies. It also tracks and analyzes competitive developments, such as joint ventures, mergers and acquisitions, new developments, and Research and Development (R&D) activities, in market.

Get a Sample: https://www.precedenceresearch.com/sample/1549

COVID-19 Impact

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the DRUG DISCOVERY OUTSOURCING market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Major companies operating in this area

  • Albany Molecular Research Inc.
  • EVOTEC
  • Laboratory Corporation of America Holdings
  • GenScript
  • Pharmaceutical Product Development, LLC.
  • Charles River
  • WuXiAppTec
  • Merck & Co., Inc.
  • Thermo Fisher Scientific Inc.
  • Dalton Pharma Services
  • Oncodesign
  • Jubilant Biosys
  • DiscoverX Corporation
  • QIAGEN

Market Segmentation

By Workflow

  • Target Identification & Screening
  • Lead Identification & Candidate Optimization
  • Target Validation & Functional Informatics
  • Preclinical Development
  • Others

By Therapeutic Area

  • Oncology
  • Cardiovascular
  • Gastrointestinal
  • Neurology
  • Respiratory
  • Others

By Drug Type

  • Biologics
  • Small Molecules

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Major highlights of Report:

  • Figures related to sales volume, market remuneration, and segmental shares
  • Featuring market dynamics
  • Growth prospects and expansion graph
  • PROCON study of direct & indirect sales channels
  • Profiles of prominent traders, dealer, and distributors in the industry

Geographical landscape: North America, Europe, Asia-Pacific, South America, Middle East and Africa

  • Industry forecasts based on region and at country level
  • Data about sales volume recorded, industry share held, and profit margins amassed
  • Overall remuneration and estimated growth rate for each regional market

Major Key Points Covered in Report:

Executive Summary: It includes key trends of the DRUG DISCOVERY OUTSOURCING market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the DRUG DISCOVERY OUTSOURCING market based on production and revenue.

Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.

Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the DRUG DISCOVERY OUTSOURCING market.

Market Segments: This part of the report discusses product, application and other segments of the DRUG DISCOVERY OUTSOURCING market based on market share, CAGR, market size, and various other factors.

Research Methodology: This section discusses the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Drug Discovery Outsourcing Market 

5.1. COVID-19 Landscape: Drug Discovery Outsourcing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Drug Discovery Outsourcing Market, By Workflow

8.1. Drug Discovery Outsourcing Market, by Workflow Type, 2022-2030

8.1.1. Target Identification & Screening

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Lead Identification & Candidate Optimization

8.1.2.1. Market Revenue and Forecast (2019-2030)

8.1.3. Target Validation & Functional Informatics

8.1.3.1. Market Revenue and Forecast (2019-2030)

8.1.4. Preclinical Development

8.1.4.1. Market Revenue and Forecast (2019-2030)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Drug Discovery Outsourcing Market, By Therapeutic Area

9.1. Drug Discovery Outsourcing Market, by Therapeutic Area, 2022-2030

9.1.1. Oncology

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Cardiovascular

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Gastrointestinal

9.1.3.1. Market Revenue and Forecast (2019-2030)

9.1.4. Neurology

9.1.4.1. Market Revenue and Forecast (2019-2030)

9.1.5. Respiratory

9.1.5.1. Market Revenue and Forecast (2019-2030)

9.1.6. Others

9.1.6.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Drug Discovery Outsourcing Market, By Drug Type 

10.1. Drug Discovery Outsourcing Market, by Drug Type, 2022-2030

10.1.1. Biologics

10.1.1.1. Market Revenue and Forecast (2019-2030)

10.1.2. Small Molecules

10.1.2.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Drug Discovery Outsourcing Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.1.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.1.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.1.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.1.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.1.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.2.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.2.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.2.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.2.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.2.6.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.2.7.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.2.7.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.3.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.3.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.3.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.3.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.3.6.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.3.7.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.3.7.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.4.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.4.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.4.6.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.4.7.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.4.7.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.5.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Workflow (2019-2030)

11.5.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)

11.5.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)

Chapter 12. Company Profiles

12.1. Albany Molecular Research Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. EVOTEC

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Laboratory Corporation of America Holdings

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. GenScript

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Pharmaceutical Product Development, LLC.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Charles River

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. WuXiAppTec

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Merck & Co., Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Thermo Fisher Scientific Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Dalton Pharma Services

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

12.11. Oncodesign

12.11.1. Company Overview

12.11.2. Product Offerings

12.11.3. Financial Performance

12.11.4. Recent Initiatives

12.12. Jubilant Biosys

12.12.1. Company Overview

12.12.2. Product Offerings

12.12.3. Financial Performance

12.12.4. Recent Initiatives

12.13. DiscoverX Corporation

12.13.1. Company Overview

12.13.2. Product Offerings

12.13.3. Financial Performance

12.13.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com

 

Post a Comment

0 Comments